Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
48-week randomized open-label switch study of raltegravir replacing ritonavir-boosted protease inhibitors in virologically suppressed HIV-1 infection
2007-003401-27Phase 3Completed
- Sponsor
- Hospital Clínic de Barcelona
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of raltegravir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Hospital Clínic de Barcelona. Primary endpoint: Clinical effectiveness non-inferiority at 48 weeks. Started Dec 2007; status: completed.
02
Drugs
raltegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2007-003401-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003401-27.